Bristol-Myers Squibb (BMS; NYSE: BMY) has received marketing approval from China’s National Medical Products Administration (NMPA) for its innovative drug Camzyos (mavacamten) for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM) graded as II to III under the New York Heart Association (NYHA) functional classification. The drug is indicated to improve exercise capacity and symptoms in this patient population.
Mavacamten, the first-in-class cardiac myosin inhibitor, works by reversibly binding to myosin to address the excessive contractility and impaired relaxation that are hallmarks of HCM. Clinical studies have demonstrated that mavacamten can significantly reduce left ventricular outflow tract (LVOT) pressure gradient and improve NYHA heart function grading, thereby enhancing patient mobility and quality of life. The drug gained its initial approval in the U.S. in April 2022 for the treatment of class II-III obstructive HCM (oHCM) and has since received approvals in other significant markets, including South Korea, Macau, and Singapore in Asia. Notably, Hainan Bo’ao Medical Pilot Zone has been the first to apply the drug in January this year.- Flcube.com
